ReviewCells2022
Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance.
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects.Medical oncology (Northwood, London, England) · 2025Review
- Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Targeting ILT4 to Improve Immunotherapy Efficacy in Solid Tumour: From Bench to Bedside.ImmunoTargets and therapy · 2025Review
- Research trends of cellular immunotherapy for primary liver cancer: A bibliometric analysis.Human vaccines & immunotherapeutics · 2024Article
- Evaluation of the safety and efficiency of cytotoxic T cell therapy sensitized by tumor antigens original from T-ALL-iPSC in vivo.Cancer innovation · 2024Article
- NECTIN-4-redirected T cell Antigen Coupler T cells bearing CD28 show superior antitumor responses against solid tumors.Frontiers in immunology · 2024Article
- Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment.International journal of nanomedicine · 2024Review
- Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application.Frontiers in immunology · 2024Review
- Adoptive Immunotherapy and High-Risk Myeloma.Cancers · 2023Review
- Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma.Blood advances · 2023Article
- The Cellular and Molecular Immunotherapy in Prostate Cancer.Vaccines · 2022Review
- Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma.Cells · 2022Review
- Immunotherapy for the treatment of multiple myeloma.Frontiers in immunology · 2022Review
- Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Despite the substantial improvement of therapeutic approaches, multiple myeloma (MM) remains mostly incurable. However, immunotherapeutic and especially T cell-based approaches pioneered the therapeutic landscape for relapsed and refractory disease recently. Targeting B-cell maturation antigen (BCMA) on myeloma cells has been demonstrated to be highly effective not only by antibody-derived constructs but also by adoptive cellular therapies. Chimeric antigen receptor (CAR)-transgenic T cells lead to deep, albeit mostly not durable responses with manageable side-effects in intensively pretreated patients. The spectrum of adoptive T cell-transfer covers synthetic CARs with diverse specificities as well as currently less well-established T cell receptor (TCR)-based personalized strategies. In this review, we want to focus on treatment characteristics including efficacy and safety of CAR- and TCR-transgenic T cells in MM as well as the future potential these novel therapies may have. ACT with transgenic T cells has only entered clinical trials and various engineering strategies for optimization of T cell responses are necessary to overcome therapy resistance mechanisms. We want to outline the current success in engineering CAR- and TCR-T cells, but also discuss challenges including resistance mechanisms of MM for evading T cell therapy and point out possible novel strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.